

## LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT W** 

WX0000003826 F 12/05/1988 34 Y

**Referral Testing** 

Collected: 09/26/2023 11:38 Received: 09/26/2023 11:38

<u>Test Name</u> <u>Result</u> <u>Flag Ref-Ranges</u> <u>Units</u> <u>Site</u>

HIV-1 Genotype DETECTED AB QCRL

HIV Subtype: B

2	sistance Mutations Detected edicted
	·····!
NRTIs	!!
ZDV (zidovudine or Retrovir)	! NO!
ABC (abacavir or Ziagen)	! NO!
ddI (didanosine or Videx)	! NO!
3TC (lamivudine or Epivir)	! NO!
FTC (emtricitabine or Emtriv	a) ! NO!
d4T (stavudine or Zerit)	! NO!
TDF (tenofovir or Viread)	! NO!
	!!
	! !
NNRTIS	!!!
ETR (etravirine or Intelence	) !YES!V106I/M,E138E/Q,Y181Y/
EFV (efavirenz or Sustiva)	!YES!K103N,V106I/M,Y181Y/C
NVP (nevirapine or Viramune)	!YES!K103N,V106I/M,Y181Y/C
RPV (rilpivirine or Edurant)	!PRB!E138E/Q,Y181Y/C
DOR (doravirine or Pifeltro)	! NO!
	11
	!!!
PIs	!!
FPV (fos-amprenavir or Lexiv	
IDV (indinavir or Crixivan)	! NO!
NFV (nelfinavir or Viracept)	! NO!
SQV (saquinavir or Invirase)	! NO!
LPV (lopinavir or Kaletra)	! NO!
ATV (atazanavir or Reyataz)	! NO!
TPV (tipranavir or Aptivus)	! NO!
DRV (darunavir or Prezista)	! NO!
	!!!
PRB = PROBABLE OR EMERGING R	!!

PRB = PROBABLE OR EMERGING RESISTANCE

OTHER MUTATIONS DETECTED:

RT GENE MUTATIONS: K70K/Q,V179I/V,R211K PR GENE MUTATIONS: M36I/M,L63C,I93L

The Quest Diagnostics Sep 2022 Interpretation Algorithm The method used in this test is RT-PCR and sequencing of the HIV-1 polymerase gene.

The phrases "resistance predicted" and "probable

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,  $\,$  . - NOT TESTED

F326000050 WX0000003826 Printed D&T: 09/26/23 11:39 Ordered By: KAJAL SITWALA, MD, PhD WX00000000002353

Kajal V. Sitwala, MD, PhD - Medical Director Form: MM RL1 PAGE 1 OF 2



## LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT W** 

WX0000003826 F 12/05/1988 34 Y

**Referral Testing** 

Collected: 09/26/2023 11:38 Received: 09/26/2023 11:38

<u>Test Name</u> <u>Result</u> <u>Flag Ref-Ranges</u> <u>Units</u> <u>Site</u>

or emerging resistance" refer to the application of the interpretive rules. The FDA has not reviewed all of the interpretive rules used by the laboratory to predict drug resistance. FDA may not currently recognize some of the HIV gene mutations reported as predictive of drug resistance, but the laboratory considers these mutations to be associated with resistance to anti-viral drugs based on current clinical or scientific studies. The test has been validated pursuant to CLIA regulations and is not considered investigational or for research use only. Treatment decisions should be made in consideration of all relevant clinical and laboratory findings and the prescribing information for the drugs.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Test Performed at: Quest Diagnostics Nichols Institute 33608 Ortega Highway San Juan Capistrano, CA 92675-2042

I Maramica MD, PhD

Performing Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

Reported Date: 2023.09.26 11:39

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F326000050 WX0000003826 Printed D&T: 09/26/23 11:39 Ordered By: KAJAL SITWALA, MD, PhD WX00000000002353

Kajal V. Sitwala, MD, PhD - Medical Director Form: MM RL1 PAGE 2 OF 2